在度-时间曲线监测计划下实施药剂师驱动的万科米辛区域,使用贝叶斯模型在门诊亲肠道抗菌疗法中进行贝叶斯模型
Eric Gillett1,2, Muneerah M Aleissa3, Jeffrey C Pearson1,2
1Department of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Open forum infectious diseases
|November 7, 2024
概括
与传统的低谷监测相比,在门诊患者中监测度-时间曲线 (AUC) 下的药剂驱动的万科米辛区域显著降低了毒性. 这种AUC方法提高了针对严重的甲素耐药黄金葡萄球菌感染的万科米辛治疗安全性.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 传染性疾病 传染性疾病
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 目前的指导方针建议在度-时间曲线 (AUC) 下的24小时区域对严重的甲素耐药黄金葡萄球菌感染的最小抑制度比监测.
- 有限的数据存在于安全性,可行性和有效性,在门诊环境中监测万科米辛AUC.
- 贝叶斯软件能够对单一度的AUC进行估计,与需要两种度的传统方法不同.
研究的目的:
- 评估药剂师驱动的门诊患者的万科米辛AUC监测计划的安全性和有效性.
- 为了比较菌素AUC监测和传统的低谷监测之间的毒性发生率.
主要方法:
- 进行了一个单中心,准实验,中断时间序列研究.
- 使用贝叶斯模型实施了两阶段的万科米辛AUC监测 (目标400-600毫克·小时/升).
- 一组对照组接受了传统的基于低谷的万科米辛监测.
主要成果:
- 毒性发生率在AUC监测组 (6.3%) 与低谷基组 (23.3%;P = .01) 相比显著较低.
- AUC组具有较少的无法使用的万科米辛度 (0%与6%相比;P < .01).
- 两组之间90天全因死亡率或再入院率没有显著差异.
结论:
- 实行药剂师驱动的万科米辛AUC监测计划减少了门诊患者的毒性.
- 以AUC为指导的米素治疗是一种安全有效的策略,用于门诊治疗严重的MRSA感染.
相关概念视频
Pharmacovigilance
776
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
776
Analysis of Population Pharmacokinetic Data
235
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
235
Clearance Models: Compartment Models
53
Clearance measures drug elimination from the central compartment, including plasma and highly perfused organs like kidneys and liver. Its calculation varies depending on pharmacokinetic models and administration routes. The one-compartment model, for instance, portrays the pharmacokinetics of polar drugs such as aminoglycoside antibiotics administered intravenously and readily excreted in urine. In this case, clearance is influenced by the terminal rate constant (λz) and the total volume...
53
Pharmacokinetic Models: Overview
597
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
597
One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation
399
This lesson introduces two critical methods in pharmacokinetics, the Wagner-Nelson and Loo-Riegelman methods, used for estimating the absorption rate constant (ka) for drugs administered via non-intravenous routes. The Wagner-Nelson method relates ka to the plasma concentration derived from the slope of a semilog percent unabsorbed time plot. However, it is limited to drugs with one-compartment kinetics and can be impacted by factors like gastrointestinal motility or enzymatic degradation.
On...
On...
399
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
32
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
32


